Dramatic AAGP™ Concentration Reductions Show Continued Skin Cell Preservation

PROTOKINETIX INC. (PKTX: OTCBB)
Vancouver, British Columbia, January 10, 2006

Dr. John Todd, President and CEO of ProtoKinetix, Inc., announces today the results of additional human skin tests requested by a major European cosmetic corporation. “This corporation, who has been instrumental in directing some of PKTX’s testing protocols and procedures, asked that we evaluate the preservative effect of AAGP™ on human skin cells using very low concentrations.” The exceptional results that PKTX achieved with higher concentrations were viewed as being far in excess of the requirements for the cosmetic industry.

The company repeated the earlier skin cell trials in the presence of H2O2 (hydrogen peroxide) and UV-c (ultraviolet rays) at body core temperature of 37°C using only 1mg/ml and 5mg/ml. Dr. Samer Hussein (lead scientist at ProteoCell) reports that even at these miniscule concentration levels, there was only a marginal decline in the preservative effect. After 24-hours, the human skin cells subjected to these extreme conditions that were not treated with AAGP™ were 100% dead. The skin cells treated with 5mg/ml of AAGP™ had 80% of the cells alive and healthy. Even at only 1mg/ml, over 50% of the exposed cells were still viable and healthy.

About ProtoKinetix:

ProtoKinetix Inc. is a scientific development company whose mission is the advancement of human health care. The Company’s first entry into the commercial market place will be the launch of the first synthetic age-arresting glycoprotein (AAGP™). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development in the areas of cell, tissue and organ preservation.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements.  Some information included in this press release contains statements that are forward-looking.  Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company.  For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

On behalf of the Board of Directors,
Dr. John Todd, President

Company Office:                       
Suite # 1500           
885 West Georgia Street           
Vancouver, BC  V6C 3E8          

Investor Contact:
BCGU, Business Consulting Group Unlimited
In the U.S.:  (888) 772-1288
Outside the U.S.: (760) 230.2300 ext 206